FDA approves treatment-free remission label update for Tasigna

FDA updated the label of Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) to reflect that some chronic myelogenous leukemia (CML)

Read the full 200 word article

User Sign In